61 related articles for article (PubMed ID: 31602268)
1. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer.
Zheng Q; Gao J; Yin P; Wang W; Wang B; Li Y; Zhao C
Cancer Sci; 2020 Feb; 111(2):383-394. PubMed ID: 31830330
[TBL] [Abstract][Full Text] [Related]
2. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
3. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
4. Enhanced peripheral blood miR-324-5p is associated with the risk of metabolic syndrome by suppressing ROCK1.
Guo J; Yang C; Lin Y; Hu G; Wei J; Zhang X; Chen X; Li J
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158727. PubMed ID: 32353552
[TBL] [Abstract][Full Text] [Related]
5. Associations of urinary polycyclic aromatic hydrocarbons with albuminuria in U.S. adults, NHANES 2003-2014.
Li J; Fan H; Liu K; Li X; Fan D; Lu X; Xia Y; Cao Y; Xiao C
Ecotoxicol Environ Saf; 2020 Jun; 195():110445. PubMed ID: 32203772
[TBL] [Abstract][Full Text] [Related]
6. CD155: A Multi-Functional Molecule in Tumor Progression.
Molfetta R; Zitti B; Lecce M; Milito ND; Stabile H; Fionda C; Cippitelli M; Gismondi A; Santoni A; Paolini R
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019260
[TBL] [Abstract][Full Text] [Related]
7. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies.
Ma L; Ma J; Sun X; Liu H
Invest New Drugs; 2023 Jun; 41(3):522-531. PubMed ID: 37198354
[TBL] [Abstract][Full Text] [Related]
8. Immune status for monitoring and treatment of bladder cancer.
Pan S; Li S; Zhan Y; Chen X; Sun M; Liu X; Wu B; Li Z; Liu B
Front Immunol; 2022; 13():963877. PubMed ID: 36159866
[TBL] [Abstract][Full Text] [Related]
9. Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.
Mukherjee AG; Wanjari UR; Namachivayam A; Murali R; Prabakaran DS; Ganesan R; Renu K; Dey A; Vellingiri B; Ramanathan G; Doss C GP; Gopalakrishnan AV
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146572
[TBL] [Abstract][Full Text] [Related]
10. Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis.
Mansorunov D; Apanovich N; Apanovich P; Kipkeeva F; Muzaffarova T; Kuzevanova A; Nikulin M; Malikhova O; Karpukhin A
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943606
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour.
Eldh M; Mints M; Hiltbrunner S; Ladjevardi S; Alamdari F; Johansson M; Jakubczyk T; Veerman RE; Winqvist O; Sherif A; Gabrielsson S
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209558
[TBL] [Abstract][Full Text] [Related]
12. Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics.
Bogen JP; Grzeschik J; Jakobsen J; Bähre A; Hock B; Kolmar H
Front Oncol; 2021; 11():672262. PubMed ID: 34123841
[TBL] [Abstract][Full Text] [Related]
13. New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges.
Allegra A; Pioggia G; Innao V; Musolino C; Gangemi S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924049
[TBL] [Abstract][Full Text] [Related]
14. Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.
Marcucci F; Rumio C
Cells; 2021 Apr; 10(4):. PubMed ID: 33921301
[TBL] [Abstract][Full Text] [Related]
15. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
16. Silenced lncRNA SNHG14 restrains the biological behaviors of bladder cancer cells via regulating microRNA-211-3p/ESM1 axis.
Feng R; Li Z; Wang X; Ge G; Jia Y; Wu D; Ji Y; Wang C
Cancer Cell Int; 2021 Jan; 21(1):67. PubMed ID: 33482820
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Middelburg J; Kemper K; Engelberts P; Labrijn AF; Schuurman J; van Hall T
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466732
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
19. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
Ma W; Ma J; Lei T; Zhao M; Zhang M
J Cancer; 2019; 10(21):5153-5161. PubMed ID: 31602268
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
